Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoid Tumor 2Sarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1

Interventions

Everolimus 6Sunitinib 3Octreotide 3cabozantinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Injections 2Fluorouracil 2Capecitabine 2Bevacizumab 2recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1X-Rays 1Thalidomide 1Temozolomide 1Streptozocin 1Sorafenib 1Phantoms, Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × ganitumab × Endocrine × Clear all
NCT01024387 2018-03-08

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 7 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡